GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Equity

Q32 Bio (Q32 Bio) Debt-to-Equity : 0.41 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Debt-to-Equity?

Q32 Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.65 Mil. Q32 Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.50 Mil. Q32 Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $48.77 Mil. Q32 Bio's debt to equity for the quarter that ended in Mar. 2024 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Q32 Bio's Debt-to-Equity or its related term are showing as below:

QTTB' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.32   Med: -0.71   Max: 0.41
Current: 0.41

During the past 3 years, the highest Debt-to-Equity Ratio of Q32 Bio was 0.41. The lowest was -2.32. And the median was -0.71.

QTTB's Debt-to-Equity is ranked worse than
71.63% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs QTTB: 0.41

Q32 Bio Debt-to-Equity Historical Data

The historical data trend for Q32 Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Debt-to-Equity Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
0.22 -2.32 -0.71

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial -2.32 N/A -1.11 -0.71 0.41

Competitive Comparison of Q32 Bio's Debt-to-Equity

For the Biotechnology subindustry, Q32 Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Debt-to-Equity falls into.


Q32 Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Q32 Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.416 + 49.424) / -71.476
=-0.71

Q32 Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.648 + 15.499) / 48.769
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio  (NAS:QTTB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Q32 Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Debt-to-Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.q32bio.com
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024